查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571896

全球血液腫瘤檢測市場

Hemato Oncology Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 92 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球血液腫瘤檢測市場（美國）預計將達到 142 億美元

全球血液腫瘤檢測市場預計 2023 年為 49 億美元，預計到 2030 年將達到 142 億美元，2023-2030 年分析期間複合年成長率為 16.3%。血液腫瘤檢測 血液腫瘤檢測服務是本報告分析的細分市場之一，預計複合年成長率為 15.4%，到分析期結束時將達到 86 億美元。在分析期間，血液腫瘤測量套件部分的複合年成長率預計為 17.7%。

美國市場預估13億美元，中國預估複合年增率20.7%

預計 2023 年美國血液腫瘤檢測市場規模將達 13 億美元。中國作為全球第二大經濟體，預計2030年市場規模將達36億美元，2023-2030年分析期間複合年成長率為20.7%。其他值得注意的區域市場包括日本和加拿大，預計在分析期間複合年成長率分別為 11.5% 和 13.7%。在歐洲，德國的複合年成長率預計約為 12.6%。

全球血液腫瘤檢測市場－主要趨勢與促進因素總結

血液腫瘤檢測如何改變癌症診斷？

血液腫瘤檢測專門診斷白血病、淋巴瘤和骨髓瘤等血癌，已成為現代癌症診斷的基石。這些測試包括分子診斷、細胞遺傳學和流式細胞技術，以識別癌細胞、基因突變和其他生物標記物，以便早期檢測和選擇標靶治療。血癌盛行率的增加和個人化醫療的興起極大地推動了對血液腫瘤檢測的需求。這個市場不僅對於癌症診斷至關重要，而且對於監測疾病進展和評估治療效果至關重要，為臨床醫生提供有關患者管理的寶貴見解。

技術進步如何影響血液腫瘤學檢測？

分子診斷、次世代定序(NGS) 和液態切片技術的技術進步徹底改變了血液腫瘤檢測。 NGS 能夠實現全面的基因組分析，並幫助識別可針對特定治療方法的突變，從而推進精準腫瘤學領域的發展。液態切片可分析血液中的循環腫瘤 DNA，為傳統組織切片檢查提供了一種侵入性較小的替代方案，可實現早期診斷並持續監測癌症進展。人工智慧和生物資訊工具在資料分析中的整合進一步提高了測試結果的準確性，並實現更快、更準確的診斷。這些創新為更個人化的治療計劃和改善血液腫瘤學患者的治療結果鋪平了道路。

細分市場和應用如何定義血液腫瘤檢測市場？

檢測類型包括分子檢測、流式細胞技術、免疫組化等，其中能夠檢測特定基因突變的分子檢測比例最大。聚合酵素鏈鎖反應(PCR) 和次世代定序(NGS) 等治療技術正在主導市場，能夠對癌細胞進行詳細分析，並為個人化治療提供關鍵資訊。血液腫瘤學檢測的應用包括診斷、預後預測和治療監測，其中診斷檢測是最重要的應用，因為早期檢測對於提高存活率至關重要。該市場由醫院、診斷實驗室和研究機構驅動，其中醫院由於擁有先進的檢測技術而成為最大的最終用戶。

推動血液腫瘤檢測市場成長的因素有哪些？

血液腫瘤檢測市場的成長是由多種因素推動的，例如血癌盛行率的增加、分子診斷的進步以及個人化醫療的興起。對早期準確癌症檢測的需求不斷成長，導致分子檢測和 NGS 技術廣泛採用。旨在改善癌症診斷和增加癌症研究資金的政府措施也對市場成長做出了重大貢獻。此外，標靶治療和免疫療法的發展增加了對先進診斷測試來識別特定生物標記和突變的需求。新興市場診斷能力的擴大以及對液態切片等微創檢測方法的更多關注是市場成長的進一步驅動力。

受訪企業範例（36家知名企業）

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Archerdx, Inc.
  • Arup Laboratories, Inc.
  • Asuragen, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Molecularmd（Subsidiary of Icon PLC）
  • Qiagen NV
  • Sanofi SA
  • Thermo Fisher Scientific, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP21944

Global Hemato Oncology Testing Market to Reach US$14.2 Billion by 2030

The global market for Hemato Oncology Testing estimated at US$4.9 Billion in the year 2023, is expected to reach US$14.2 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2023-2030. Hemato Oncology Testing Services, one of the segments analyzed in the report, is expected to record a 15.4% CAGR and reach US$8.6 Billion by the end of the analysis period. Growth in the Hemato Oncology Assay Kits segment is estimated at 17.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 20.7% CAGR

The Hemato Oncology Testing market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 20.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.5% and 13.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR.

Global Hemato Oncology Testing Market - Key Trends and Drivers Summarized

How Is Hemato Oncology Testing Transforming Cancer Diagnosis?

Hemato oncology testing, which focuses on diagnosing blood cancers such as leukemia, lymphoma, and myeloma, has become a cornerstone of modern cancer diagnostics. These tests include molecular diagnostics, cytogenetics, and flow cytometry to identify cancerous cells, genetic mutations, and other biomarkers that aid in early detection and targeted therapy selection. The increasing incidence of blood cancers, coupled with the rise in personalized medicine, has significantly driven demand for hemato oncology testing. This market is essential not only for diagnosing cancer but also for monitoring disease progression and assessing treatment efficacy, offering clinicians valuable insights into patient management.

How Are Technological Advancements Shaping Hemato Oncology Testing?

Technological advancements in molecular diagnostics, next-generation sequencing (NGS), and liquid biopsy techniques have revolutionized hemato oncology testing. NGS allows for comprehensive genomic profiling, helping identify mutations that may be targeted by specific therapies, thereby advancing the field of precision oncology. Liquid biopsies, which analyze circulating tumor DNA in the bloodstream, offer a minimally invasive alternative to traditional tissue biopsies, enabling earlier diagnosis and continuous monitoring of cancer progression. The integration of AI and bioinformatics tools in data analysis has further enhanced the accuracy of test results, allowing for quicker and more precise diagnoses. These innovations are paving the way for more personalized treatment plans, improving patient outcomes in hemato oncology.

How Are Segments and Applications Defining the Hemato Oncology Testing Market?

Test types include molecular tests, flow cytometry, and immunohistochemistry, with molecular tests holding the largest share due to their ability to detect specific genetic mutations. Technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) dominate the market, enabling detailed analysis of cancerous cells and providing crucial information for personalized treatment. Applications of hemato oncology testing include diagnosis, prognosis, and treatment monitoring, with diagnostic testing being the most significant application as early detection remains critical in improving survival rates. The market is driven by hospitals, diagnostic laboratories, and research institutions, with hospitals being the largest end-users due to their access to advanced testing technologies.

What Factors Are Driving the Growth in the Hemato Oncology Testing Market?

The growth in the hemato oncology testing market is driven by several factors, including the increasing prevalence of blood cancers, advancements in molecular diagnostics, and the rise of personalized medicine. The growing demand for early and accurate cancer detection has led to wider adoption of molecular tests and NGS technologies. Government initiatives aimed at improving cancer diagnostics, along with increased funding for cancer research, are also significant contributors to market growth. Furthermore, the development of targeted therapies and immunotherapies has heightened the need for advanced diagnostic tests to identify specific biomarkers and mutations. The expansion of diagnostic capabilities in emerging markets and the growing focus on minimally invasive testing methods, such as liquid biopsies, are additional drivers of market growth.

Select Competitors (Total 36 Featured) -

  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Archerdx, Inc.
  • Arup Laboratories, Inc.
  • Asuragen, Inc.
  • Bio-Rad Laboratories, Inc.
  • F. Hoffman-La Roche Ltd.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Molecularmd (Subsidiary of Icon PLC)
  • Qiagen N.V.
  • Sanofi SA
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Hemato Oncology Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Hematologic Cancers Drives Demand for Hemato Oncology Testing
    • Technological Advancements in Molecular Diagnostics Strengthen Growth of Hemato Oncology Testing Market
    • Increasing Focus on Personalized Medicine Expands Addressable Market for Precision Oncology Testing
    • Growing Adoption of Next-Generation Sequencing (NGS) in Hemato Oncology Testing Spurs Market Innovation
    • Rising Availability of Liquid Biopsy Solutions Generates Demand for Non-Invasive Cancer Testing
    • Expansion of Companion Diagnostics in Hemato Oncology Strengthens Business Case for Testing Solutions
    • Rising Focus on Early Cancer Detection and Screening Expands Hemato Oncology Testing Market
    • Growth in Targeted Cancer Therapies Drives Demand for Comprehensive Genetic Testing
    • Surge in Adoption of Immuno-Oncology Therapies Spurs Need for Advanced Testing Solutions
    • Rising Awareness and Accessibility of Cancer Testing in Emerging Markets Expands Market Opportunities
    • Growing Use of Artificial Intelligence and Machine Learning in Cancer Testing Accelerates Innovation
    • Regulatory Push for Precision Medicine in Oncology Strengthens Adoption of Hemato Oncology Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hemato Oncology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Assay Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Assay Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for IHC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for IHC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for IHC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cytogenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cytogenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Hemato Oncology Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hodgkin Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hodgkin Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hodgkin Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • JAPAN
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • CHINA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • EUROPE
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Hemato Oncology Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • FRANCE
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • GERMANY
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Hemato Oncology Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • INDIA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Hemato Oncology Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Hemato Oncology Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Hemato Oncology Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030
  • AFRICA
    • Hemato Oncology Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Component - Services and Assay Kits - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Hemato Oncology Testing by Component - Services and Assay Kits Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Hemato Oncology Testing by Component - Percentage Breakdown of Value Sales for Services and Assay Kits for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Hemato Oncology Testing by Technology - PCR, IHC, NGS, Cytogenetics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Hemato Oncology Testing by Technology - Percentage Breakdown of Value Sales for PCR, IHC, NGS, Cytogenetics and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Hemato Oncology Testing by Cancer Type - Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Hemato Oncology Testing by Cancer Type - Percentage Breakdown of Value Sales for Hodgkin Lymphoma, Other Cancer Types, Leukemia and Lymphoma for the Years 2014, 2024 & 2030

IV. COMPETITION